Researchers have made some fascinating discoveries about the treatment of migraine.
Calcitonin gene-related peptide (CGRP) has long been associated with the development of migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway, including erenumab, galcanezumab and fremanezumab, have shown promise in clinical trials and real-life studies.
Initially, the European Headache Federation recommended treatment with CGRP(-R) mAbs for 6 to 12 months, followed by interruption. However, the actual data reveal a surprising trend: a continued increase in migraine frequency on discontinuation of treatment. While free CGRP levels remain stable, total CGRP levels decrease significantly after three months without treatment. Bertin Bioreagent’s CGRP kit provides accurate measurements, improving migraine management and quality of life for sufferers.
